pirenzepine has been researched along with Adrenal Cancer in 2 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takashima, A | 1 |
| Kenimer, JG | 1 |
| Michel, AD | 1 |
| Stefanich, E | 1 |
| Whiting, RL | 1 |
2 other studies available for pirenzepine and Adrenal Cancer
| Article | Year |
|---|---|
Muscarinic-stimulated norepinephrine release and phosphoinositide hydrolysis in PC12 cells are independent events.
Topics: Adrenal Gland Neoplasms; Animals; Atropine; Cell Line; Diamines; Hydrolysis; Kinetics; Methacholine | 1989 |
PC12 phaeochromocytoma cells contain an atypical muscarinic receptor binding site.
Topics: Adrenal Gland Neoplasms; Animals; Binding, Competitive; Cell Membrane; Kinetics; Myocardium; N-Methy | 1989 |